Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700681 | 1.00 | ENPP2 (0.40) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL8518543 | 0.86 | ENPP2 (0.40) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL8518538 | 0.86 | ENPP2 (0.40) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL8846372 | 0.81 | ENPP2 (0.44) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL8846881 | 0.81 | ENPP2 (0.42) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL20525220 | 0.81 | ENPP2 (0.38) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL7784260 | 0.80 | ENPP2 (0.43) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL7979145 | 0.80 | ENPP2 (0.43) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL7779693 | 0.80 | ENPP2 (0.43) | ENPP2CYP11B1CYP11B2FLT3TYRO3 | |
| SCHEMBL30210402 | 0.80 | ENPP2 (0.43) | ENPP2CYP11B1CYP11B2FLT3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794405-B2 | Alicyclic imidazoles as H3 agents | MERCK & CO., INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040029943-A1 | Novel alicylic imidazoles as H3 agents | MERCK SHARP & DOHME CORP. | 2004-02-12 | — | — | US | disclosed |
| US-20020042400-A1 | Novel alicyclic imidazoles as H3 agents | GLIATECH, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029943-A1 | Novel alicylic imidazoles as H3 agents | HRH3, HRH2, HRH4 | ENPP2 440/4885CYP11B1 1442/4885CYP11B2 1187/4885 |
| US-20020042400-A1 | Novel alicyclic imidazoles as H3 agents | HRH3, HRH2, HRH4 | ENPP2 401/4885CYP11B1 1345/4885CYP11B2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.